The adoptive transfer of in vitro generated tumor antigen-specific cytotoxic T lymphocytes (CTL) provides a promising approach to the immunotherapy of cancer. A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients.
INTRODUCTION
The identification of tumor-associated antigens (TAAs) recognized by T cells has led to the development of clinical studies, which target malignant cells by augmenting the specific cellular immune response. 1 These approaches include vaccination strategies, in which the TAAs are presented in a potentially immunogenic context to induce antigen-specific T-cell responses in vivo and adoptive cell transfer strategies, in which TAA-reactive T cells are generated ex vivo and then infused to the patient to increase the number of tumor-reactive effector cells in vivo. Successful tumor eradication by adoptively transferred T cells has been demonstrated in murine models, 2 but the translation into the clinical practice has been cumbersome. The proof of principle for adoptive T-cell therapy was its use to control relapse of hematologic diseases and viral infections after allogeneic bone marrow transplantation. [3] [4] [5] Recent success of adoptive T-cell therapy using ex vivo expanded autologous tumor-reactive T cells has fuelled optimism that this concept may find a place as a specific therapy for some malignant diseases. [6] [7] [8] In this study of adoptive T-cell therapy we target the melanoma antigen Melan-A, 9 ,10 which belongs to the group of melanocyte differentiation antigens. Melan-A is an ideal target antigen because of its high immunogenicity and preferential expression on melanoma cells.
We have developed improved methods for the generation of Melan-A specific cytotoxic T lymphocyte (CTL) lines from patients peripheral blood lymphocytes (PBL) and have administered these CTL to patients with melanoma demonstrating that ex vivo generated Melan-A specific CTL can be detected in the patients blood after adoptive transfer and localize preferentially to tumor. 11 We now report on the results from a phase I clinical trial of adoptively transferred Melan-A specific CTL in patients with advanced melanoma.
PATIENTS AND METHODS

Patients and Treatment Schedule
Thirteen HLA-A2 ϩ patients with stage IV melanoma, who were refractory to standard therapeutic regimens, were eligible for treatment. The trial was designed and conducted in accordance with the Declaration of Helsinki. The therapy protocol was approved by the institutional ethics committee and registered with the regulatory state authority. All patients gave written informed consent before enrolling onto the study. HLA typing of peripheral blood mononuclear cells (PBMC) was performed at the University of Regensburg (Regensburg, Germany) HLA typing laboratory. Eosinophil levels were determined using established standards at the University of Regensburg clinical laboratory.
Eligible HLA-A2 ϩ patients received at least three intravenous infusions of Melan-A-specific CTL suspended in 100 mL of 5% human serum albumin at 2-week intervals. Each T-cell infusion was accompanied by a 6-day course of subcutaneous interleukin-2 (IL-2; 3 ϫ 10 6 U daily). Tumor response was defined according to WHO criteria. Patient response was assessed using computed tomography (CT) or positron emission tomography (PET) scan studies at 2 weeks after the third T-cell transfer and at regular intervals thereafter. Adoptive T-cell therapy was continued at 4-week intervals in those patients who had at least stable disease or objective response after therapy. For subcutaneous melanoma, a mixed response (ie, complete regression of one target lesion while one other progresses), although formally classified as stable or progressive disease in the WHO classification, was documented as well.
Immune monitoring was performed before T-cell transfer and at least at 1, 6, 24, and 48 hours after T-cell infusion. In some patients additional blood samples were obtained at various time points. PBMC were isolated by Ficoll density gradient centrifugation.
Generation of Melan-A-Specific CTL Lines From PBL
Melan-A-specific CTL lines were generated as previously described.
11,12
PBMC were obtained by leukapheresis and CD8 ϩ T cells, purified by magnetic separation, stimulated with mature dendritic cells (DC) pulsed with the HLA-A2-restricted modified Melan-A peptide (Melan-A 26-35L ; ELAGIGILTV; Clinalfa AG, Laeufelingen, Switzerland) and human ␤ 2 -microglobulin (10 g/ mL) at a responder to stimulator ratio of 5:1 to 10:1. CTL lines were cultured in complete medium, containing 10% human AB serum and 1% to 2% T-cell growth factor. 12,13 After four cycles of stimulation, phenotypic and functional analysis of T cells was performed.
Immunophenotyping and Peptide Major Histocompatibility Complex Tetramer Staining
Surface marker analysis of CTL lines and DC was performed using a FACScalibur (Becton Dickinson, San Jose, CA) and the CellQuest software (Becton Dickinson). Fluorescence conjugated monoclonal antibodies (mAbs) were purchased from Becton Dickinson. To detect Melan-A-specific T cells in the CTL lines and PBMC, phycoerythrin (PE) -labeled HLA-A2-tetramer (TM) that had been folded around ELAGIGILTV (Melan-A 26-35L ) or SLYNTVATL (HIVgag) were prepared by Beckman Coulter (Fullerton, CA). For combined TM and annexin-V staining, annexin-V-FITC (PharMingen, San Diego, CA) was used.
Chromium Release Assay
The cytotoxic activity of T cells was measured by a 4 hours 51 chrom (Cr) release assay as described.
11 Effector-target ratios were calculated based on the number of Melan-A-TM ϩ T cells in the effector population in order to accurately compare different T-cell populations. 
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control gp100 280-288 peptide (Clinalfa), or the allogeneic melanoma cell lines Na-8-MEL (HLA-A2 
Immunohistochemical Staining
For detection of Melan-A and anti-gp100 expression in formalin-fixed melanoma tissue embedded in paraffin, the anti-Melan-A (A103; Novocastra, Newcastle, United Kingdom) and antigp100 (HMB45; Dako, Hamburg, Germany) mAbs were used. Bound mAb was detected using the diaminobenzidine method and counterstained with hematoxylin.
Statistical Analysis
Correlation between the total number of transferred Melan-A-TM ϩ CTL and the frequency of circulating Melan-A-TM ϩ T cells within CD8 ϩ PBL was done using Spearman nonparametric rank correlation. Only correlations such that r s more than 0.70 would be interpreted as being strong correlations.
RESULTS
Patient Characteristics
Eleven of 13 patients with refractory malignant melanoma completed at least three adoptive T-cell infusions and were assessable. One patient was withdrawn because of rapid disease progression, in one patient (number 12) we were unable to generate sufficient amounts of Melan-A specific CTL. The demographic and clinical characteristics of this patient population is shown in Table  1 . All patients had extensive metastatic disease with lung and/or liver (patients 1 to 4 and 8), bone (patients 2 and 3), lymph node (LN; patients 1, 4 to 6, and 8), and skin metastases (patients 1, 2, and 7); Immunohistochemical analysis of Melan-A expression in tumor biopsies obtained before CTL transfer demonstrated abundant expression of Melan-A in all examined samples (Fig 1 and Table 1;  patients 1, 3, 4, and 6 ).
Characteristics of Melan-A-Specific CTL Adoptively Transferred to Patients
A total of 52 T-cell infusions were administered, and on average 2.11 ϫ10 Table 2 .
The frequency of Melan-A-specific T cells as determined by Melan-A-TM staining was 38.3% Ϯ 17.3% (mean Ϯ standard deviation) within total CD8 ϩ lymphocytes. As shown in Figure 2 (for CTL lines from patients 8, 9, and 11), Melan-A-specific T cells consisted of Ag-primed CTL, showing either CD45RA low /CCR7
-terminally differentiated effector cells or CD45RA
Ϫ effector memory cells.
14 Melan-A-specific CTL expressed activation markers such as CD95, HLA-DR, and CD69 (data not shown) but were negative for CD62L (Fig 2) . Functional analysis of the CTL lines revealed a strong cytotoxic activity against Melan-A-pulsed T2 cells and allogeneic HLA-A2
ϩ Melan-A-expressing melanoma cells (Fig 2) .
Adverse Events and Selective Loss of Melan-A Expression in the Tumor After Adoptive CTL Transfer
Clinical adverse effects were usually mild and consisted of chills and fever WHO grade 1 to 2 in seven of 11 patients that typically occurred within 6 to 8 hours post-CTL infusion (Table 1) . Patients were monitored for signs and symptoms for autoimmunity because Melan-A is also expressed on melanocytes. No physical signs of autoimmunity were observed in any of the patients. One patient (number 3) developed a local inflammatory response with erythema at the tumor site 6 days after the second T-cell transfer.
The laboratory value with the greatest change from baseline was the peripheral blood eosinophil count. An increase in eosinophils up to 51% was observed in seven of 11 patients (Table 1 ). Figure 3A shows the sharp increase in the proportion of eosinophils for patient 5 at 24 hours post-CTL transfer. Eosinophil counts were still about two to three times higher 2 weeks after T-cell therapy as compared with the preinfusion value. Eosinophilia has been previously reported with IL-2 treatment regimens 15, 16 and is linked primarily to production of IL-5. Significant amounts of IL-5 could be also detected in the supernatant of the transferred CTL product (data not shown) suggesting that the T cells itself could be in part responsible for the eosinophilia.
To analyze whether the T-cell transfer combined with IL-2 administration alters the distribution of lymphocyte subpopulations in patients PBL, we performed flow cytometric analysis in four melanoma patients before each transfer. No changes in total lymphocyte counts could be observed after therapy. In two of four patients, the percentage of CD3 -/CD16 ϩ /CD56 ϩ natural killer (NK) cells increased from 9% to 24% and from 5% to 19% of total lymphocytes, respectively (data not shown), and a slight increase of CD3 ϩ /CD16 ϩ /CD56 ϩ NK-T cells was observed. The T-cell therapy did not influence the percentage of circulating CD4 ϩ CD25 high T regulatory cells. For two patients, Melan-A expression by tumor cells was evaluated in LN metastases obtained before and after third T-cell transfer. In both patients the preinfusion tumor revealed a high expression of Melan-A, while the postinfusion metastases showed a selective loss of the Melan-A protein (Fig 3B) . Expression of the gp100 protein was not affected by Melan-A-specific CTL.
In Vivo Frequency and Persistence of Transfused Melan-A-Specific CTL
The frequency and persistence of transferred Melan-A-specific CTL was determined in serial PBL samples from 10 treated patients using Melan-A TM. All patients showed an increase of circulating Melan-A-TM ϩ CD8 ϩ T cells (mean, 10.8-fold; range, two-to 43-fold) and a peak Melan-A-specific T-cell frequency 48 hours after transfer, comprising on average 0.67% of total peripheral blood CD8 ϩ cells (range, 0.03% to 1.77%). The pre-and peak postinfusion levels of circulating Melan-A TM ϩ CD8 ϩ T cells after each T-cell transfer are summarized in Table 2 .
In two patients, additional blood samples were collected at 6 days post-T-cell infusion and revealed the highest frequency of circulating Melan-A-specific CTL (Fig 4A) . Since the frequency had decreased at 14 days after transfer, these findings suggest the disappearance of the transfused T cells from the peripheral blood mainly in the second week. 
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There was a strong correlation between the total number of transferred Melan-A TM ϩ CTL and the peak frequency of circulating Melan-A TM ϩ T cells (Fig 4D; r s ϭ 0.857; P Ͻ .0001). Repetitive CTL infusions revealed an identical pattern in the frequencies of Melan-A TM ϩ T cells at 24 hours post-T-cell infusion as demonstrated for patient 5 up to the sixth transfer (Fig 4B) .
Annexin-V staining of Melan-A TM/CD8-gated T cells obtained from PBMC of four patients before, 6 hours, and 48 hours post-T-cell infusion demonstrated that the transferred T cells do not undergo apoptosis within 48 hours post-transfer (Fig 4C) .
Clinical Response
All patients had progressive disease before inclusion onto the study. Three of 11 patients experienced objective clinical responses to T-cell transfusion (one complete response [24 monthsϩ], one partial response [11 months], one mixed response with complete regression of one metastatic lesion [14 months] but progressive disease of one other metastasis; Table 1 ). Regression of melanoma lesions after T-cell transfer was seen exclusively in subcutaneous and lymphatic, but not in visceral metastases. The three responders are documented in Figure 5 either by PET or CT scan, showing a complete regression of abdominal LN metastases in patient 11 (Fig 5A) , a mixed response of subcutaneous metastases in patient 8 (Fig 5B) , and a partial response of a paratracheal LN metastasis in patient 5 (Fig 5C) . PET results could be confirmed either by CT (online only Appendix Fig A1 for patient 11) or by physical examination (patient 8).
Defective DC Differentiation in a Melanoma Patient Prevents In Vitro Induction of TAA Specific CTL
In one patient (patient 12) we were unable to generate high amounts of Melan-A-specific CTL (frequency between 0.15% to 2.5% Melan-A-TM ϩ T cells after four rounds of in vitro stimulation). We therefore asked whether the antigen presenting cells in this patient may be functionally defective and studied the phenotype and function of mature DC derived from monocytes of this particular HLA-A2 ϩ melanoma patient and two HLA-A2 ϩ healthy donors. These data, summarized in the online only Appendix, revealed a defective DC function caused by abnormal differentiation of the cells.
DISCUSSION
The observation that activated T cells are responsible for the rejection of tumors in rodent models has led to the development of cellular immunotherapies for the treatment of cancer patients based on stimulating T-cell reactivity against TAAs. The adoptive transfer of ex vivo expanded immune effector cells has several advantages compared with active immunization and can overcome many of the tumor immune escape mechanisms such as production of immunosuppressive factors 17 or expression of coinhibitory molecules by the tumor.
18
This phase I study demonstrates, that adoptively transferred antigen-specific CTL lines, recognizing the Melan-A antigen, do survive in vivo for several weeks, traffic to tumor sites, and can induce a clinical response in metastatic melanoma patients. The following conclusions emerge from this study, which included 52 T-cell infusions in 11 melanoma patients: sufficient numbers of antigen-specific CTL can be generated from melanoma patients by four rounds of in vitro stimulation of purified CD8
ϩ PBL with peptide-pulsed DC; adoptive Melan-A-specific T-cell therapy is possible without major adverse effects or signs of autoimmune disease; and clinical antitumor responses were observed in three of 11 patients, with regression of LN and subcutaneous metastases.
One of the greatest challenges for adoptive T-cell immunotherapy is currently the generation of large numbers of antigen-specific CTL after short-term culture. Our study is different from most other adoptive T-cell therapies with respect to the T-cell product: the T cells used in the National Institutes of Health study presented by Dudley and colleagues, 8 were derived from tumor-infiltrating lymphocytes and were rapidly expanded in vitro with CD3-specific mAb and high doses of IL-2 in the presence of allogeneic PBMCs. In three other clinical studies tumor-reactive T-cell clones, derived either from patient's PBL or tumor-infiltrating lymphocytes, were transferred. 6, 19, 20 In contrast, we used antigen-specific T-cell lines isolated from patient's PBL by short-term in vitro stimulation with autologous antigen-loaded DC. These independently stimulated CTL cultures, that can be expanded up to 400-fold in a 3-week period, were freshly prepared for each individual T-cell transfer without any freezing of the T-cell product. Cytokines, such as IL-2, acting together with signals through the T-cell receptor and costimulatory signals, can function as accelerators or brakes for T-cell proliferation and differentiation. 21 Recent studies have demonstrated that IL-2 and other common gamma-chain receptor cytokines, including IL-7 and IL-15, act at different stages of the immune response to promote proliferation and survival. 22 We used a T-cell growth factor for in vitro stimulation of antigen-specific T-cell lines, that was isolated from stimulated PBMCs, and mainly consists of IL-2, IL-4, tumor necrosis factor-␣, and interferon-␥ (A. Mackensen, unpublished observations). Further studies are warranted to demonstrate that this cytokine combination is more effective in generating large numbers of antigen-specific CTL than IL-2, IL-7, and/or IL-15.
The toxicities observed in our T-cell study included the expected adverse effects of low-dose IL-2 such as fever and chills, but no serious toxicities associated with high-dose IL-2, such as vascular leakage syndrome. 8 Despite the high frequencies of circulating Melan-A-specific CTL in up to 2% of total CD8 ϩ T cells, no autoimmunity directed against normal melanocytes, such as vitiligo, was observed in our patients.
The persistence of the transferred CTL and their migration to the tumor is crucial for the success of adoptive immunotherapy. Similar to the study of Yee et al, 6 low-dose IL-2 was administered in order to prolong survival of the transferred CTL. Maximal frequencies of circulating Melan-A-TM ϩ T cells could be observed at day 6 post-T-cell infusion followed by a decrease at day 14, suggesting a coincidence of prolonged T-cell survival and IL-2 treatment after CTL transfer. Recent studies have shown that the administration of a lymphodepleting chemotherapy can augment the survival and in vivo expansion of adoptively transferred CTL. 8, 23 Studies in mice suggested that lymphodepletion before adoptive T-cell transfer works in two ways: the depletion of host cells creates empty space, which the transferred cells fill by homeostatic proliferation. The depletion also rids the host of regulatory T cells, which would otherwise dampen the function of transferred tumor-specific T cells. Recently, Gattinoni et al 24 have shown that lymphodepletion removes endogenous cellular elements that act as sinks for IL-7 and IL-15 required for augmenting T-cell functionality.
Recent studies also suggest that the telomere length of the transferred T cells correlates with in vivo T-cell persistence after adoptive transfer. 25 Senescence of long-term expanded cells might be a specific problem for T-cell therapy because the polyclonal expansion of adult T cells in vitro is limited to 30 to 40 cell divisions due to loss of telomeres. This might explain the shorter survival of transferred T-cell clones 19 compared with T-cell lines used in our study. Specific migration of PBL-derived TAA-specific CTLs to tumor sites has been shown previously in our 111 In labeling studies.
11 These data are supported by the selective downregulation of Melan-A protein in the tumor after repetitive T-cell transfer, suggesting a strong pressure of the transferred Melan-A-specific CTL on the tumor cells after entering the tumor.
In summary, we demonstrate that the transfer of antigenspecific CTL directed against Melan-A is safe, and that the CTL lines persist in vivo. They migrate to tumor sites and mediate tumor-specific immunity in some patients. Although the results show that our adoptively transferred T cells can induce even complete tumor responses, they also reveal limitations of this approach, as it is limited to patients expressing HLA alleles for which TAAencoded peptides are available. The selective loss of the target antigen Melan-A after repetitive T-cell transfer illustrates that multiple TAAs should be targeted in future clinical trials. Adoptive transfer of antigen-specific CTL after in vitro stimulation with antigen-pulsed DC is a promising approach for a targeted therapy of patients with malignant diseases.
